MYGN took a beating after it's guidance underwhelm last quarter. I do believe that the reaction was overdone. MYGN has healthy revenue streams and growing drug and generics demand. TA confirms a re-entering into trading range of: PT 1: $25.00 for a ~20%+ return. PT 2: $30.00 for a 50% return.
Yesterday AST closed its session gapping up and breaking an upward triangle which might become a strong bullish opportunity. Although general downward motion is still intact, double bottom which was formed at the beginning of July and triangle breakout have every chance to finish with bearish mood. We would project the price to go up and reach at least $3.60 where...
With increased volume and bullish engulfing pattern which finished double bottom formation, OVAS is an excellent pick to buy this week. Last week global fertility company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. The business earned $0.19 million during the quarter, compared to analysts’ expectations of $0.21...
Oh., how great... management bought some stock at $0.75 and they took back a public offering. The stock climbed and has momentum, but why? The company is still producing revenues of $0 and ops are getting more expensive. Earnings keep getting more negative, don't expect anything good to come out of their reporting coming up in August. Short at ~1.15 this morning...
Indicators showing a potential bullish swing, reasons shown on chart.
Fundamentals : Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Ligand Pharmaceuticals has a compelling business model that offers higher than average return with lower than average risk. Ligand's P/E of 8 is cheap as I...
Fundamentals : Amedisys provides home health, and hospice and personal care services. The market Amedisys serves is expected to grow in the future. The company's earnings growth has averaged 46.3% over the past three years, while the industry has seen its bottom line increase at a far lesser rate of 3.2%. With the macro environment proving favorable for Amedisys,...
Fundamentals : It's not every day that you find a solid company operating in a growing industry which also happens to be a dividend aristocrat. Medtronic is such a company. Company is operating in the healthcare industry, being the largest medical technology company in the world. Today before market open company releases tis earnings report. Technical : Price...
Money flow is at the lowest point of 2016 attract
This shows the stock prices of Canada's largest medical marijuana company.
This tracks Canada's largest medical marijuana company's stock prices.
You can thank that little price hiking hedge fund manager and people like Bill Ackman for the Healthcare/Pharmaceutical correction. Looking at the weekly using Fibs as reference points i believe healthcare over the next few months will begin to sell. I have a target of the 1.618 extension of 59.76 and a second target of 53.31. I'm using XLV to short because...
Johnson & Johnson has seen extreme price consolidation since last November. Since they are a highly diversified healthcare company, currency translations affect their bottom line quite substantially. With the recent contraction of the US Dollar, Johnson & Johnson has broken out of a prolonged trading range. If the dollar continues to contract against other foreign...
XLV could move nicely as the healthcare stocks continue to advance, watch for a breakout with volume to take the trade and stop 8% down
Almost Family has done a 38.2% Fibonacci Retracement. Almost Family has grown EPS by +1340% quarter over quarter, and EPS forecasts for this company are rising fast. This company has had an EPS surprise for the last 8 quarters! The company has an excellent P/S of 0.8. The catalyst for growth is that Americans are living longer and that means more home health...